PMID- 33750922
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20230129
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Linking)
VI  - 21
IP  - 5
DP  - 2021 May
TI  - Antigen presentation in cancer: insights into tumour immunogenicity and immune 
      evasion.
PG  - 298-312
LID - 10.1038/s41568-021-00339-z [doi]
AB  - Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, 
      has shown tremendous success in treating cancer, although success still remains 
      limited to a fraction of patients. To date, clinically effective CD8(+) T cell 
      responses appear to target predominantly antigens derived from tumour-specific 
      mutations that accumulate in cancer, also called neoantigens. Tumour antigens are 
      displayed on the surface of cells by class I human leukocyte antigens (HLA-I). To 
      elicit an effective antitumour response, antigen presentation has to be 
      successful at two distinct events: first, cancer antigens have to be taken up by 
      dendritic cells (DCs) and cross-presented for CD8(+) T cell priming. Second, the 
      antigens have to be directly presented by the tumour for recognition by primed 
      CD8(+) T cells and killing. Tumours exploit multiple escape mechanisms to evade 
      immune recognition at both of these steps. Here, we review the tumour-derived 
      factors modulating DC function, and we summarize evidence of immune evasion by 
      means of quantitative modulation or qualitative alteration of the antigen 
      repertoire presented on tumours. These mechanisms include modulation of antigen 
      expression, HLA-I surface levels, alterations in the antigen processing and 
      presentation machinery in tumour cells. Lastly, as complete abrogation of antigen 
      presentation can lead to natural killer (NK) cell-mediated tumour killing, we 
      also discuss how tumours can harbour antigen presentation defects and still evade 
      NK cell recognition.
FAU - Jhunjhunwala, Suchit
AU  - Jhunjhunwala S
AUID- ORCID: 0000-0003-3484-0588
AD  - Genentech Inc., South San Francisco, CA, USA. jhunjhunwala.suchit@gene.com.
FAU - Hammer, Christian
AU  - Hammer C
AUID- ORCID: 0000-0003-4548-7548
AD  - Genentech Inc., South San Francisco, CA, USA.
FAU - Delamarre, Lelia
AU  - Delamarre L
AUID- ORCID: 0000-0001-9122-5181
AD  - Genentech Inc., South San Francisco, CA, USA. delamarre.lelia@gene.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210309
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/*immunology
MH  - Antigens, Neoplasm/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Humans
MH  - Immune Evasion/*immunology
MH  - Immunomodulation
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Neoplasms/*immunology/pathology
EDAT- 2021/03/23 06:00
MHDA- 2021/05/11 06:00
CRDT- 2021/03/22 18:52
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/03/23 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
PHST- 2021/03/22 18:52 [entrez]
AID - 10.1038/s41568-021-00339-z [pii]
AID - 10.1038/s41568-021-00339-z [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2021 May;21(5):298-312. doi: 10.1038/s41568-021-00339-z. Epub 
      2021 Mar 9.